

Boris Juelg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4639930/publications.pdf>

Version: 2024-02-01

66
papers

4,444
citations

147726

31
h-index

118793

62
g-index

71
all docs

71
docs citations

71
times ranked

8234
citing authors

#	ARTICLE	IF	CITATIONS
1	Repurposing the CRISPR-Cas9 system for targeted DNA methylation. <i>Nucleic Acids Research</i> , 2016, 44, 5615-5628.	6.5	612
2	Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. <i>Nature Medicine</i> , 2010, 16, 1147-1151.	15.2	448
3	HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. <i>Nature</i> , 2016, 535, 556-560.	13.7	400
4	Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 1184-1195.	13.9	371
5	Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1535.	3.8	260
6	HIV-1-Specific Interleukin-21 ⁺ CD4 ⁺ T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8 ⁺ T Cell Function. <i>Journal of Virology</i> , 2011, 85, 733-741.	1.5	173
7	A high-throughput single-cell analysis of human CD8+ T cell functions reveals discordance for cytokine secretion and cytolysis. <i>Journal of Clinical Investigation</i> , 2011, 121, 4322-4331.	3.9	140
8	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. <i>Lancet HIV</i> , 2019, 6, e259-e268.	2.1	139
9	Humoral signatures of protective and pathological SARS-CoV-2 infection in children. <i>Nature Medicine</i> , 2021, 27, 454-462.	15.2	137
10	Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	106
11	Infrequent Recovery of HIV from but Robust Exogenous Infection of Activated CD4 ⁺ T Cells in HIV Elite Controllers. <i>Clinical Infectious Diseases</i> , 2010, 51, 233-238.	2.9	98
12	Enhanced Anti-HIV Functional Activity Associated with Gag-Specific CD8 T-Cell Responses. <i>Journal of Virology</i> , 2010, 84, 5540-5549.	1.5	91
13	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , 2019, 26, 336-346.e3.	5.1	88
14	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	87
15	Discrete SARS-CoV-2 antibody titers track with functional humoral stability. <i>Nature Communications</i> , 2021, 12, 1018.	5.8	82
16	Differential Neutralization of Human Immunodeficiency Virus (HIV) Replication in Autologous CD4 T Cells by HIV-Specific Cytotoxic T Lymphocytes. <i>Journal of Virology</i> , 2009, 83, 3138-3149.	1.5	80
17	Limited HIV Infection of Central Memory and Stem Cell Memory CD4+ T Cells Is Associated with Lack of Progression in Viremic Individuals. <i>PLoS Pathogens</i> , 2014, 10, e1004345.	2.1	76
18	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76

#	ARTICLE	IF	CITATIONS
19	Early cross-coronavirus reactive signatures of humoral immunity against COVID-19. <i>Science Immunology</i> , 2021, 6, eabj2901.	5.6	67
20	Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. <i>Nature Medicine</i> , 2022, 28, 1288-1296.	15.2	44
21	The Duffy Antigen Receptor for Chemokines Null Promoter Variant Does Not Influence HIV-1 Acquisition or Disease Progression. <i>Cell Host and Microbe</i> , 2009, 5, 408-410.	5.1	43
22	Possession of HLA Class II DRB1*1303 Associates with Reduced Viral Loads in Chronic HIV-1 Clade C and B Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 803-809.	1.9	43
23	Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response. <i>Nature Communications</i> , 2021, 12, 6853.	5.8	41
24	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	40
25	Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. <i>Nature Medicine</i> , 2021, 27, 1718-1724.	15.2	39
26	Bat-associated Histoplasmosis Can Be Transmitted at Entrances of Bat Caves and Not Only Inside the Caves. <i>Journal of Travel Medicine</i> , 2008, 15, 133-136.	1.4	38
27	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , 2017, 91, .	1.5	38
28	Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 369-374.	1.4	37
29	Nephrotic-Range Proteinuria Following Pamidronate Therapy in a Patient With Metastatic Breast Cancer: Mitochondrial Toxicity as a Pathogenetic Concept?. <i>American Journal of Kidney Diseases</i> , 2006, 47, 1075-1080.	2.1	37
30	Lack of Duffy Antigen Receptor for Chemokines: No Influence on HIV Disease Progression in an African Treatment-Naive Population. <i>Cell Host and Microbe</i> , 2009, 5, 413-415.	5.1	37
31	Neutralizing antibodies for HIV-1 prevention. <i>Current Opinion in HIV and AIDS</i> , 2019, 14, 318-324.	1.5	34
32	Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022. <i>JCI Insight</i> , 2021, 6, .	2.3	34
33	Epithelial adhesion molecules can inhibit HIV-1-specific CD8+ T-cell functions. <i>Blood</i> , 2011, 117, 5112-5122.	0.6	31
34	High Avidity CD8+ T Cells Efficiently Eliminate Motile HIV-Infected Targets and Execute a Locally Focused Program of Anti-Viral Function. <i>PLoS ONE</i> , 2014, 9, e87873.	1.1	31
35	Broadly neutralizing antibodies for HIV-1 prevention and therapy. <i>Seminars in Immunology</i> , 2021, 51, 101475.	2.7	28
36	Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. <i>JCI Insight</i> , 2019, 4, .	2.3	25

#	ARTICLE	IF	CITATIONS
37	Factors Predicting Discordant Virological and Immunological Responses to Antiretroviral Therapy in HIV-1 Clade C Infected Zulu/Xhosa in South Africa. <i>PLoS ONE</i> , 2012, 7, e31161.	1.1	20
38	Impact of Select Immunologic and Virologic Biomarkers on CD4 Cell Count Decrease in Patients with Chronic HIV-1 Subtype C Infection: Results from Sinikithemba Cohort, Durban, South Africa. <i>Clinical Infectious Diseases</i> , 2009, 49, 956-964.	2.9	19
39	Mining for humoral correlates of HIV control and latent reservoir size. <i>PLoS Pathogens</i> , 2020, 16, e1008868.	2.1	19
40	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. <i>Cell Reports</i> , 2020, 33, 108502.	2.9	19
41	Treatment Interruption in HIV Therapy: a SMART Strategy?. <i>Infection</i> , 2006, 34, 186-188.	2.3	18
42	HIV Genetic Diversity: Any Implications for Drug Resistance?. <i>Infection</i> , 2005, 33, 299-301.	2.3	17
43	Progression of renal impairment under therapy with tenofovir. <i>Aids</i> , 2005, 19, 1332-1333.	1.0	17
44	Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. <i>ELife</i> , 2021, 10, .	2.8	16
45	Therapeutic Vaccines for the Treatment of HIV. <i>Translational Research</i> , 2020, 223, 61-75.	2.2	14
46	Susceptibility to HIV/AIDS: An Individual Characteristic We Can Measure?. <i>Infection</i> , 2005, 33, 160-162.	2.3	13
47	US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab563.	0.4	12
48	Learning from HIV-1 to predict the immunogenicity of T-Cell epitopes in SARS-CoV-2. <i>IScience</i> , 2021, 24, 102311.	1.9	11
49	Severe hepatotoxicity associated with the combination of enfuvirtide and tipranavir/ritonavir: case report. <i>Aids</i> , 2006, 20, 1563.	1.0	10
50	Viral Rebound Kinetics Correlate with Distinct HIV Antibody Features. <i>MBio</i> , 2021, 12, .	1.8	10
51	The Paradox of Incomplete CD4+Cell Count Restoration Despite Successful Antiretroviral Treatment and the Need to Start Highly Active Antiretroviral Therapy Early. <i>Clinical Infectious Diseases</i> , 2009, 48, 795-797.	2.9	8
52	Lack of Association between HLA Class II Alleles and <i>In Vitro</i> Replication Capacities of Recombinant Viruses Encoding HIV-1 Subtype C Gag-Protease from Chronically Infected Individuals. <i>Journal of Virology</i> , 2012, 86, 1273-1276.	1.5	8
53	Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells. <i>Cell Reports</i> , 2021, 35, 109167.	2.9	8
54	Antibodies for Human Immunodeficiency Virus-1 Cure Strategies. <i>Journal of Infectious Diseases</i> , 2021, 223, S22-S31.	1.9	7

#	ARTICLE	IF	CITATIONS
55	Novel immunological strategies for HIV-1 eradication. Journal of Virus Eradication, 2015, 1, 232-236.	0.3	6
56	Lymph node fibrosis: a structural barrier to unleashing effective vaccine immunity. Journal of Clinical Investigation, 2018, 128, 2743-2745.	3.9	4
57	Landscape of Human Immunodeficiency Virus Neutralization Susceptibilities Across Tissue Reservoirs. Clinical Infectious Diseases, 2022, 75, 1342-1350.	2.9	4
58	Broadly Neutralizing Antibodies: Magic Bullets against HIV?. Immunity, 2016, 44, 1253-1254.	6.6	3
59	What's New in HIV/AIDS? Neutralizing HIV Antibodies: Do they Really Protect?. Infection, 2005, 33, 405-407.	2.3	2
60	What's New in HIV/AIDS? Chemokine Receptor Antagonists: A New Era of HIV Therapy?. Infection, 2005, 33, 408-410.	2.3	2
61	Clinical News from the XVI International AIDS Conference: The Attempt of a Summing up. Infection, 2006, 34, 294-297.	2.3	1
62	HIV-1 Latency by Transition. Immunity, 2017, 47, 611-612.	6.6	1
63	S04-06 OA. Polyvalent Gag-specific CD8 T-cells with enhanced functional properties are enriched in HIV-1 clade C infected individuals with lower viral loads. Retrovirology, 2009, 6, .	0.9	0
64	Association of interleukin-10 promoter genetic variants with T-cell and B-cell activation in HIV-1 infection. Retrovirology, 2012, 9, .	0.9	0
65	Integrative Genomic Analysis of HIV-Specific CD8+ T Cells Reveals That PD-1 Inhibits T Cell Function by Upregulating the AP-1 Transcription Factor BATF.. Blood, 2009, 114, 916-916.	0.6	0
66	HIV Cure Strategies. , 2019, , 59-66.		0